NCT05672173View on ClinicalTrials.gov

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 2, 2023

Primary Completion Date

September 10, 2025

Study Completion Date

September 10, 2025

Conditions
Recurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaRichter Syndrome
Interventions
PROCEDURE

Biopsy

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood specimen collection

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy and/or aspiration

PROCEDURE

Computed Tomography

Undergo PET/CT

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

DRUG

Ibrutinib

Given PO

BIOLOGICAL

Lisocabtagene Maraleucel

Given IV

BIOLOGICAL

Nivolumab

Given IV

PROCEDURE

Pheresis

Undergo apheresis

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (2)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER